Bafna Pharmaceuticals Limited
NSE: BAFNAPH
NSE
74.84
-0.03 (-0.04%)
Prev Close
74.87
Open Price
77.58
Volume
1,888
Today Low / High
73.1 / 77.59
52 WK Low / High
69 / 113
Range
71 - 79
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 74.84, with a change of -0.03 (-0.04006945%). The expected target range on the NSE is between 71 - 79. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
17 Apr
77.58
-3.53%
16 Apr
72.65
3.06%
15 Apr
74.00
1.18%
11 Apr
72.51
-0.01%
09 Apr
72.50
0.00%
08 Apr
72.00
0.69%
07 Apr
74.82
-3.77%
04 Apr
74.05
-1.42%
03 Apr
76.24
-2.87%
02 Apr
72.01
6.33%
01 Apr
75.00
-0.25%
28 Mar
76.00
-1.58%
27 Mar
77.61
-1.65%
26 Mar
78.50
-1.15%
25 Mar
78.95
-0.49%
24 Mar
78.61
0.43%
21 Mar
81.50
-3.56%
20 Mar
80.69
1.62%
Bafna Pharmaceuticals Limited Graph
Bafna Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bafna Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 74.84, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 74.84 | 75.59 | 68.03 - 83.15 |
| 76.34 | 61.07 - 91.60 | ||
| 77.09 | 53.96 - 100.21 | ||
| Bearish Scenario | 74.84 | 74.09 | 66.68 - 81.50 |
| 73.34 | 58.67 - 88.01 | ||
| 72.59 | 50.82 - 94.37 |
Overview of Bafna Pharmaceuticals Limited
ISIN
INE878I01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,264
Market Cap
1,770,437,492
Last Dividend
0
Official Website
IPO Date
2012-11-12
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of BAFNAPH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2013-09-19 | September 19, 13 | 0.6 | 0.06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 152.47 Cr | 107.25 Cr | 45.22 Cr | 0.2966 | 1.54 Cr | 19.31 Cr | 23.77 Cr | 7.35 Cr | 3.11 | 14.63 Cr | 0.0482 |
| 2023-03-31 | 115.35 Cr | 76.59 Cr | 38.76 Cr | 0.3360 | 0.72 Cr | 1.48 Cr | 11.77 Cr | 11.34 Cr | 4.79 | 18.99 Cr | 0.0983 |
| 2022-03-31 | 85.14 Cr | 51.54 Cr | 33.60 Cr | 0.3946 | 1.47 Cr | 1.99 Cr | 6.64 Cr | 5.22 Cr | 2.21 | 11.23 Cr | 0.0613 |
| 2021-03-31 | 71.22 Cr | 62.23 Cr | 8.98 Cr | 0.1261 | 1.36 Cr | 0.72 Cr | 6.14 Cr | 5.83 Cr | 2.46 | 10.39 Cr | 0.0818 |
| 2020-03-31 | 42.47 Cr | 40.54 Cr | 1.93 Cr | 0.0454 | 1.01 Cr | 1.21 Cr | -1.96 Cr | -1.88 Cr | -104.54 | 1.39 Cr | -0.0442 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.40 Cr | 147.68 Cr | 66.84 Cr | 80.8390 Cr | 24.39 Cr | 22.99 Cr | 29.64 Cr | 50.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 54.0830 Cr |
| 2023-03-31 | 7.81 Cr | 129.58 Cr | 56.13 Cr | 73.4546 Cr | 22.92 Cr | 15.11 Cr | 22.22 Cr | 40.23 Cr | 0.00 Cr | 1.22 Cr | 0.00 Cr | 46.4763 Cr |
| 2022-03-31 | 0.02 Cr | 90.14 Cr | 28.18 Cr | 61.9637 Cr | 11.06 Cr | 11.04 Cr | 20.28 Cr | 38.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 22.0127 Cr |
| 2021-03-31 | 0.75 Cr | 86.47 Cr | 29.69 Cr | 56.7711 Cr | 15.79 Cr | 12.25 Cr | 15.44 Cr | 36.80 Cr | 0.89 Cr | 0.00 Cr | 0.00 Cr | 24.3088 Cr |
| 2020-03-31 | 8.19 Cr | 71.06 Cr | 20.12 Cr | 50.9454 Cr | 3.02 Cr | -5.17 Cr | 11.41 Cr | 35.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 17.0996 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 9.4848 Cr | -15.0536 Cr | -0.8454 Cr | -6.3634 Cr | -6.4134 Cr | 1.3960 Cr | -15.5782 Cr | 7.3479 Cr | 1.4654 Cr | 0.0000 Cr | -7.4231 Cr |
| 2023-03-31 | 4.9525 Cr | -7.4932 Cr | 10.1771 Cr | -3.2661 Cr | 7.6364 Cr | 7.8094 Cr | -6.7187 Cr | 11.7691 Cr | 11.8645 Cr | 0.0000 Cr | -1.9391 Cr |
| 2022-03-31 | 9.7283 Cr | -6.5442 Cr | -4.8148 Cr | 2.1871 Cr | -1.6307 Cr | 0.1730 Cr | -7.5412 Cr | 5.2163 Cr | -4.7266 Cr | 0.0000 Cr | -4.8372 Cr |
| 2021-03-31 | -13.6089 Cr | -5.3454 Cr | 12.2798 Cr | -19.7036 Cr | -6.6764 Cr | 1.8037 Cr | -6.0947 Cr | 5.8267 Cr | 12.3684 Cr | 0.0000 Cr | -4.0309 Cr |
| 2020-03-31 | -34.2680 Cr | 32.7748 Cr | 7.2713 Cr | -35.6968 Cr | 5.7669 Cr | 8.4801 Cr | -1.4288 Cr | -1.8834 Cr | -43.2403 Cr | 0.0000 Cr | -2.1292 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 33.19 Cr | 23.63 Cr | 9.56 Cr | 0.2881 | 1.41 Cr | 0.95 Cr | 0.40 | 3.24 Cr | 0.0286 |
| 2024-09-30 | 40.32 Cr | 27.76 Cr | 12.57 Cr | 0.3117 | 2.22 Cr | 2.62 Cr | 1.11 | 4.82 Cr | 0.0649 |
| 2024-06-30 | 33.29 Cr | 31.68 Cr | 1.61 Cr | 0.0484 | -0.23 Cr | -0.72 Cr | -0.31 | 1.37 Cr | -0.0217 |
| 2024-03-31 | 41.40 Cr | 34.89 Cr | 6.51 Cr | 0.1573 | 1.62 Cr | 1.46 Cr | 0.62 | 3.40 Cr | 0.0352 |
| 2023-12-31 | 28.44 Cr | 23.29 Cr | 5.15 Cr | 0.1811 | -3.35 Cr | -2.94 Cr | -1.24 | -1.10 Cr | -0.1035 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1.31 Cr | 0.01 Cr | 1.32 Cr | 0.00 Cr | 27.47 Cr | 74.61 Cr | 55.53 Cr | 134.16 Cr | 51.41 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | -80.84 Cr |
| 2024-03-31 | 1.40 Cr | 0.70 Cr | 1.40 Cr | 45.39 Cr | 29.64 Cr | 94.47 Cr | 50.71 Cr | 147.68 Cr | 66.84 Cr |
| 2023-12-31 | -7.86 Cr | 15.73 Cr | 7.86 Cr | 0.00 Cr | 0.00 Cr | 7.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 7.86 Cr | 0.00 Cr | 7.86 Cr | 39.83 Cr | 29.36 Cr | 90.95 Cr | 40.89 Cr | 134.87 Cr | 52.51 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -2.94 Cr | 2.54 Cr | 0.00 Cr | 0.00 Cr | 2.54 Cr | 10.41 Cr | 7.86 Cr | 0.00 Cr | 2.54 Cr |
| 2023-09-30 | 2.48 Cr | 2.48 Cr | 0.00 Cr | 0.00 Cr | 2.48 Cr | 7.86 Cr | 5.38 Cr | 0.00 Cr | 2.48 Cr |
| 2023-06-30 | 6.35 Cr | 2.43 Cr | 0.00 Cr | 0.00 Cr | 2.43 Cr | 10.24 Cr | 7.81 Cr | 0.00 Cr | 2.43 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-08-26 | August 26, 19 | 1:10 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,751.50 | ₹4,202,338,920,000.00 | ₹2,683,738.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,640.00 | ₹1,497,245,160,000.00 | ₹531,900.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.80 | ₹1,101,570,786,000.00 | ₹202,237.00 |
| Mankind Pharma Limited | MANKIND | ₹2,581.60 | ₹1,065,112,707,232.00 | ₹489,407.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,163.60 | ₹969,410,310,072.00 | ₹2,787,901.00 |
| Lupin Limited | LUPIN | ₹1,937.20 | ₹884,457,718,000.00 | ₹1,443,063.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹831.55 | ₹836,730,556,500.00 | ₹4,090,344.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,171.60 | ₹680,467,623,200.00 | ₹769,589.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,953.30 | ₹592,241,314,500.00 | ₹45,830.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,342.40 | ₹378,809,171,200.00 | ₹613,037.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,404.40 | ₹356,301,897,600.00 | ₹63,964.00 |
| Laurus Labs Limited | LAURUSLABS | ₹628.05 | ₹338,677,846,650.00 | ₹1,963,259.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,694.60 | ₹336,587,875,200.00 | ₹96,774.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,168.10 | ₹297,357,376,500.00 | ₹124,155.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,646.30 | ₹256,291,045,100.00 | ₹104,543.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,413.80 | ₹229,712,810,200.00 | ₹309,368.00 |
| Piramal Enterprises Limited | PEL | ₹995.10 | ₹224,373,157,800.00 | ₹440,877.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,746.00 | ₹218,650,000,000.00 | ₹31,887.00 |
| Eris Lifesciences Limited | ERIS | ₹1,383.00 | ₹188,266,407,000.00 | ₹41,650.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.90 | ₹167,058,893,700.00 | ₹300,134.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,821.00 | ₹164,492,147,900.00 | ₹33,908.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,967.10 | ₹149,522,615,070.00 | ₹127,499.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹827.60 | ₹148,231,436,000.00 | ₹299,818.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹918.95 | ₹146,371,274,950.00 | ₹252,814.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹467.50 | ₹113,365,945,000.00 | ₹1,134,180.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,218.00 | ₹86,615,669,200.00 | ₹2,232.00 |
| FDC Limited | FDC | ₹430.45 | ₹70,081,564,500.00 | ₹58,398.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹733.60 | ₹66,489,557,232.00 | ₹336,064.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹668.50 | ₹65,373,216,650.00 | ₹88,055.00 |
| Strides Pharma Science Limited | STAR | ₹653.00 | ₹60,182,243,100.00 | ₹289,176.00 |
| Hikal Limited | HIKAL | ₹431.60 | ₹53,216,711,600.00 | ₹794,158.00 |
| Innova Captab Limited | INNOVACAP | ₹913.20 | ₹52,257,806,076.00 | ₹59,550.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹149.93 | ₹48,655,583,460.00 | ₹540,168.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹613.95 | ₹43,225,640,910.00 | ₹15,117.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹775.95 | ₹39,355,485,645.00 | ₹55,962.00 |
| Sequent Scientific Limited | SEQUENT | ₹147.34 | ₹36,879,496,680.00 | ₹955,155.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,201.80 | ₹36,415,570,200.00 | ₹6,105.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹343.65 | ₹34,460,534,700.00 | ₹25,634.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹357.45 | ₹32,624,461,500.00 | ₹108,626.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹52.36 | ₹28,690,871,440.00 | ₹2,998,041.00 |
| Suven Life Sciences Limited | SUVEN | ₹126.32 | ₹27,547,107,680.00 | ₹168,622.00 |
| Alembic Limited | ALEMBICLTD | ₹103.97 | ₹26,697,624,436.00 | ₹491,826.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹523.60 | ₹25,160,550,800.00 | ₹47,862.00 |
| Windlas Biotech Limited | WINDLAS | ₹1,084.10 | ₹22,786,697,900.00 | ₹176,971.00 |
Key Executives
Whole-Time Director of Quality
Mr. Vinayak Dinesh Dendukuri
Gender: male
Year Born: 1987
Executive Chairman
Ms. Shanmugam Hemalatha
Gender: female
Year Born: 1975
Company Secretary & Compliance Officer
Mr. A. Mohanachandran
Gender: male
Year Born:
Chief Executive Officer
Mr. Bansilal Mahaveer Chand Bafna
Gender: male
Year Born: 1961
Chief Financial Officer
Mr. Melagiri Sridhar
Gender: male
Year Born: 1968
FAQs about Bafna Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mr. Bansilal Mahaveer Chand Bafna.
What is the current market price of the stock?
The current price is ₹74.84.
What is the 52-week price range?
The range is ₹69-113.
What is the market capitalization of the company?
The market capitalization is ₹177.04 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 41.27.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bafna Pharmaceuticals Limited (ISIN: INE878I01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹177.04 crores and an average daily volume of 2,264 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.